Adaptive Bioscience is cutting about 12% of its workforce in response to a restructuring plan.

The Seattle-based company said it will be organized around two newly-created business areas: Immune Medicine and Minimal Residual Disease. The company said the reorganization will deprioritize projects and programs that are no longer aligned with the goals of the two business areas.

Adaptive’s Immune Medicine business is comprised of its research, diagnostic, and drug discovery products and services driven by T-cell mapping efforts in partnership with Microsoft. The portfolio currently includes immunoSEQ, T-Detect, and drug discovery collaborations with Genentech and Nykode.

This reorganization will enable Adaptive to drive multiple product and service opportunities from disease-specific TCR-Antigen maps, as demonstrated by the company’s successful COVID-19 efforts.

Adaptive’s MRD business is comprised of its clonoSEQ diagnostic test offered to clinicians and the clonoSEQ assay offered to its pharmaceutical partners to support drug development and approvals. clonoSEQ is the first and only FDA-cleared assay for MRD in chronic lymphocytic leukemia (CLL), multiple myeloma (MM), and B-cell acute lymphoblastic leukemia (ALL).

This reorganization will enable Adaptive to capitalize further on the strong synergy between clinical adoption and inclusion of clonoSEQ in pharmaceutical drug development trials.

“While it is difficult to part ways with valuable team members who have made important contributions to Adaptive, we are at an inflection point in a rapidly evolving industry and workplace and believe these changes will put us in a stronger position to deliver on our mission and vision,” said Chad Robins, the company’s CEO, and co-founder. “I am confident this reorganization and new leadership in place will set Adaptive up for breakthrough growth in 2022 and beyond.”